SCHEMBL5427122

SCHEMBL5427122

CC(C)c1[c]c(C(C)C)cc(OCc2ccccn2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PARP10 Q53GL7 1/20 0.46
SYK P43405 9/20 0.44
MAOB P27338 1/20 0.43
AURKB Q96GD4 2/20 0.43
INCENP Q9NQS7 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
MAOA P21397 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
GABRA2 P47869 1/20 0.42
TLR4 O00206 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27557523 0.81 KDM4E (0.50) KDM4EALDH1A1SMN1; SMN2PARP10SYK
SCHEMBL16638704 0.78 KDM4E (0.58) KDM4EALDH1A1SMN1; SMN2PARP10SYK
SCHEMBL24301594 0.77 TLR4 (0.49) KDM4EALDH1A1SMN1; SMN2PARP10SYK
SCHEMBL28153213 0.77 KDM4E (0.53) KDM4EALDH1A1SMN1; SMN2PARP10SYK
SCHEMBL24726474 0.77 SYK (0.45) KDM4EALDH1A1SMN1; SMN2PARP10SYK
SCHEMBL5420966 0.76 MAOB (0.41) SMN1; SMN2MAOBMAOATLR4TLR2
SCHEMBL26580976 0.76 KDM4E (0.51) KDM4EALDH1A1SMN1; SMN2PARP10SYK
SCHEMBL22967390 0.74 KDM4E (0.58) KDM4EALDH1A1SMN1; SMN2PARP10SYK
SCHEMBL6445371 0.74 KCNH2 (0.67) KDM4EALDH1A1SMN1; SMN2PARP10SYK
SCHEMBL21199309 0.73 MAPT (0.59) KDM4EALDH1A1SMN1; SMN2PARP10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099891-A1 Medicinal compositions and combinations DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-05-03 US disclosed
EP-1695706-A1 MEDICINAL COMPOSITIONS AND COMBINATIONS Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-08-30 EP disclosed
US-6420381-B1 ACYL-COA: CHOLESTEROL ACYL TRANSFERASE (ACAT) INHIBITORY ACTIVITY, AND IS USEFUL AS AN AGENT FOR TREATMENT OF HYPERLIPIDEMIA AND ATHEROSCLEROSIS. SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-07-16 US disclosed
EP-1104763-A1 NAPHTHYRIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099891-A1 Medicinal compositions and combinations HMGCR, APOB, CYP46A1 KDM4E 846/4885ALDH1A1 792/4885SMN1; SMN2 4298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.